Generic placeholder image

Recent Advances in Inflammation & Allergy Drug Discovery


ISSN (Print): 2772-2708
ISSN (Online): 2772-2716


Bile Acids and SARS-CoV-2: Ursodeoxycholic Acid as a Potential Treatment of COVID-19

Author(s): Stefano Fiorucci*, Ginevra Urbani and Eleonora Distrutti

Volume 17, Issue 1, 2023

Published on: 09 June, 2023

Page: [2 - 6] Pages: 5

DOI: 10.2174/2772270817666230601124326

Murakami N, Hayden R, Hills T, et al. Therapeutic advances in COVID-19. Nat Rev Nephrol 2023; 19(1): 38-52.
[] [PMID: 36253508]
Gavriatopoulou M, Korompoki E, Fotiou D, et al. Organ-specific manifestations of COVID-19 infection. Clin Exp Med 2020; 20(4): 493-506.
[] [PMID: 32720223]
Welte T, Ambrose LJ, Sibbring GC, Sheikh S, Müllerová H, Sabir I. Current evidence for COVID-19 therapies: A systematic literature review. Eur Respir Rev: An Off J Eur Respir Soc 2021; 30(159)
Zhou Q, Zhao S, Gan L, et al. Use of non-steroidal anti-inflammatory drugs and adverse outcomes during the COVID-19 pandemic: A systematic review and meta-analysis. EClinicalMedicine 2022; 46: 101373.
[] [PMID: 35434582]
Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 2021; 9(12): 1407-18.
[] [PMID: 34480861]
Godino C, Scotti A, Maugeri N, et al. Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence-. Int J Cardiol 2021; 324: 261-6.
[] [PMID: 33002521]
Pitre T, Van Alstine R, Chick G, Leung G, Mikhail D, Cusano E. Antiviral drug treatment for nonsevere COVID-19: A systematic review and network meta-analysis. CMAJ 2022; 194(28): E969-80.
Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: A propensity score–matched control study. Nat Med 2020; 26(11): 1708-13.
[] [PMID: 32934372]
Krause PR, Fleming TR, Longini IM, et al. SARS-CoV-2 Variants and Vaccines. N Engl J Med 2021; 385(2): 179-86.
[] [PMID: 34161052]
Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19. N Engl J Med 2020; 382(22): 2158-60.
[] [PMID: 32329972]
Bruno G, Giotta M, Perelli S, De Vita G, Bartolomeo N, Buccoliero GB. Early access to oral antivirals in high-risk outpatients: Good weapons to fight COVID-19. Viruses 2022; 14(11): 2514.
[] [PMID: 36423123]
Gong X, Kang S, Guo X, Li Y, Gao H, Yuan Y. Associated risk factors with disease severity and antiviral drug therapy in patients with COVID-19. BMC Infect Dis 2021; 21(1): 549.
[] [PMID: 34112084]
Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol 2020; 76(16): 1815-26.
[] [PMID: 32860872]
Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426(6965): 450-4.
[] [PMID: 14647384]
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-80.
Nugent MA. The future of the COVID-19 pandemic: How good (or bad) can the SARS-CoV2 spike protein get? Cells 2022; 11(5): 855.
[] [PMID: 35269476]
Biagioli M, Marchianò S, Roselli R, et al. GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation. Cells 2022; 11(7): 1187.
[] [PMID: 35406751]
Akerib DS, Alsum S, Aquino C, Araújo HM, Bai X, Bailey AJ. A role for proteinase-activated receptor-1 in inflammatory bowel diseases. Gastroenterology 2012; 10(2): 21303.
Fiorucci S, Carino A, Baldoni M, Santucci L, Costanzi E, Graziosi L. Bile acid signaling in inflammatory bowel diseases. Dig Dis Sci 2020; 66(3): 674-93.
Irani AH, Steyn-Ross DA, Steyn-Ross ML, Voss L, Sleigh J. The molecular dynamics of possible inhibitors for SARS-CoV-2. J Biomol Struct Dyn 2022; 40(20): 10023-32.
[] [PMID: 34229582]
Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med 2020; 76: 14-20.
[] [PMID: 32336612]
Carino A, Moraca F, Fiorillo B, et al. Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain. Front Chem 2020; 8: 572885.
[] [PMID: 33195060]
Fiorillo B, Marchianò S, Moraca F, et al. Discovery of Bile Acid Derivatives as Potent ACE2 Activators by Virtual Screening and Essential Dynamics. J Chem Inf Model 2022; 62(1): 196-209.
[] [PMID: 34914393]
Biagioli M, Marchianò S, Roselli R, Di Giorgio C, Bellini R, Bordoni M. Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction. Biochem Pharmacol 2021; 188: 114564.
Biagioli M, Carino A, Cipriani S, Francisci D, Marchianò S, Scarpelli P. The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis. J Immunol 2017; 199(2): 718-33.
Abdulrab S, Al-Maweri S, Halboub E. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm. Med Hypotheses 2020; 143: 109897.
Rodal Canales FJ, Pérez-Campos Mayoral L, Hernández-Huerta MT, et al. Interaction of Spike protein and lipid membrane of SARS-CoV-2 with Ursodeoxycholic acid, an in-silico analysis. Sci Rep 2021; 11(1): 22288.
[] [PMID: 34782703]
Thuy PX, Bao TDD, Moon EY. Ursodeoxycholic acid ameliorates cell migration retarded by the SARS-CoV-2 spike protein in BEAS-2B human bronchial epithelial cells. Biomed Pharmacother 2022; 150: 113021.
[] [PMID: 35658221]
Brevini T, Maes M, Webb GJ, John BV, Fuchs CD, Buescher G. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature 2022.
[PMID: 36470304]
Hadj Hassine I. Covid-19 vaccines and variants of concern: A review. Rev Med Virol 2022; 32(4): e2313.
[] [PMID: 34755408]

© 2024 Bentham Science Publishers | Privacy Policy